TwinBeech Capital’s Aurinia Pharmaceuticals AUPH Stock Holding History

TwinBeech Capital’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-26,300	Closed	-$390K	–	383
2026 Q1	$390K	Buy	+26,300	New	+$384K	0.04%	399
2025 Q4	–	Sell	-51,932	Closed	-$574K	–	591
2025 Q3	$574K	Buy	+51,932	New	+$567K	0.02%	379
2024 Q1	–	Sell	-10,209	Closed	-$91.8K	–	549
2023 Q4	$91.8K	Sell	10,209 -135,136	-93%	-$1.11M	﹤0.01%	608
2023 Q3	$1.13M	Buy	+145,345	New	+$1.42M	0.02%	479
2022 Q3	–	Sell	-64,913	Closed	-$652K	–	620
2022 Q2	$652K	Buy	+64,913	New	+$726K	0.03%	395
2022 Q1	–	Sell	-37,541	Closed	-$859K	–	496
2021 Q4	$859K	Buy	+37,541	New	+$890K	0.05%	365

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TwinBeech Capital's AUPH Position: Q2 2026 in Review

TwinBeech Capital sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2026, closing a stake of 26,300 shares — an estimated $390K sold.

TwinBeech Capital first reported a position in AUPH in Q4 2021 and held it in 6 quarters. The position peaked at $1.13M in Q3 2023. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

TwinBeech Capital reported no remaining Aurinia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
TwinBeech Capital sold 26,300 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $390K.
TwinBeech Capital first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 6 quarters.
TwinBeech Capital's Aurinia Pharmaceuticals position peaked at $1.13M in Q3 2023.
281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.